Pain
Conditions
Interventions
This is a randomized, double-blind, two-arm clinical trial. A total of 72 patients will be recruited, with 36 patients in each arm. Patients will be randomized and allocated into two groups: Pregabali
s dosage, which consists of a loading dose administered two hours before surgery and maintained every 12 hours until the seventh postoperative day
The preemptive loading dose will be 150 mg, which, according to a study by Asgari (2017) comparing the effect of administering different doses of pregabalin 2 hours before laparoscopic hysterectomy, w
Sponsors
Escola Paulista de Medicina da Universidade Federal de São Paulo
Hospital Estadual de Diadema
Eligibility
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: ASA 1 to 3 by the American Society of Anesthesiology; ages between 18 and 65 years; of both sexes; with grade III or IV hemorrhoidal disease indicated for Milligam-Morgan hemorrhoidectomy
Exclusion criteria
Exclusion criteria: Patients with cardiac arrhythmias; cardiomyopathy and/or cardiac conduction disorders; psychiatric, liver, respiratory, or oncological diseases; cognitive impairments that prevent proper completion of the forms; using analgesics in the week prior to surgery; associated surgeries; hypersensitivity to medications; active user of psychoactive drugs; consent forms signed incorrectly or without signature
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected that higher pain reduction scores will be found in the group that used pregabalin in combination with other medications, based on the assumption that the postoperative visual analog scale pain score in the pregabalin group would be 35 mm, compared to 50 mm in the placebo group, with a standard deviation of 20 mm. | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcomes are expected | — |
Countries
Brazil
Contacts
Public ContactRicardo Akiba
Escola Paulista de Medicina da Universidade Federal de São Paulo
Outcome results
None listed